Lonza Group AG: o společnosti

563,40 CHF

-2,39 % dnes

Lonza Group AG (LONN.SW) je společnost ze sektoru zdravotnictví (Diagnostics & Research). Sídlí Basel, Švýcarsko. Zaměstnává přibližně 20 141 lidí. Tržní kapitalizace je 39,4 mld. CHF. Generálním ředitelem je Wolfgang Wienand Ph.D..

Základní údaje

Sektor: Zdravotnictví
Odvětví: Diagnostics & Research
Země: Švýcarsko
Sídlo: Basel
Zaměstnanci: 20 141
Generální ředitel: Wolfgang Wienand Ph.D.
Web: lonza.com
Tržní kapitalizace: 39,4 mld. CHF

Popis podnikání

Popis společnosti v originále (anglicky), zdroj Yahoo Finance.

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.